AMG-319

N/A

Report date: 2023/05/05 17:36:48
NME

Base Information

Drug NameAMG-319
Drug Alias NameAMG-319ACP-319
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphatidylinositol 3 kinase delta inhibitors
TargetsPhosphatidylinositol 3 kinase delta
Therapy Area/IndicationsHematologic NeoplasmsHead and Neck NeoplasmsLymphoma, T-Cell +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesAmgen Inc
Inactive CompaniesN/A
Active IndicationsHead and Neck Neoplasms
Inactive IndicationsHematologic NeoplasmsLymphoma, T-CellLymphoma, Mantle-Cell +[9] 

Other Information

ATC CodeN/A
Related LinksN/A